Corona Remedies Ltd

Fri 14/08/2026,15:51:55 | NSE : CORONA

₹2137.1023.90 (1.13%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 2113.20

Previous Close

₹ 2113.20

Volume

41202

Mkt Cap ( ₹ Cr)

₹ 13070.52

High

₹ 2180.90

Low

₹ 2113.20

52 Week High

₹ 2270.10

52 Week Low

₹ 1336.60

Book Value Per Share

₹ 122.12

Dividend Yield

0.46

Face Value

₹ 10.00

What's Your Call?

Collective community sentiment on Corona Remedies Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

2137.10

3

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

3

Option Chain

Analyzes market sentiment, predicts Corona Remedies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 5:57PM CORONA Remedies Limited has informed the Exchange about Transcript

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 11:26AM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    10 Aug 2026, 5:55PM Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Aug 2026, 11:20AM Intimation for Schedule of Analysts / Investor Conference

  • Corona Remedies - Updates

    7 Aug 2026, 3:54PM CORONA Remedies Limited has informed the Exchange regarding 'Machine Readable Financial results for Q1 2026-27'.

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Aug 2026, 4:25PM CORONA Remedies Limited has informed the Exchange about Link of Recording

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    3 Aug 2026, 4:21PM Audio Recording of Q1 FY27 Earnings Conference Call with Analysts / Investors

  • Corona Remedies - Copy of Newspaper Publication

    1 Aug 2026, 10:48AM CORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication

  • Corona Remedies - Investor Presentation

    31 Jul 2026, 7:37PM CORONA Remedies Limited has informed the Exchange about Investor Presentation

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Investor Presentation

    31 Jul 2026, 7:35PM Analyst/Investor presentation

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    31 Jul 2026, 5:43PM Press Release on Financial Results for Q1FY27

  • Corona Remedies - Press Release

    31 Jul 2026, 5:37PM CORONA Remedies Limited has informed the Exchange regarding a press release dated July 31, 2026, titled ""Press Release on Unaudited financial results

  • Corona Remedies - Outcome of Board Meeting

    31 Jul 2026, 5:32PM CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

  • Corona Remedies - Unaudited Financial Results For The First Quarter And Three Months Ended June 30, 2026

    31 Jul 2026, 5:28PM Unaudited Financial Results for the first quarter and three months ended June 30, 2026

  • Corona Remedies - Board Meeting Outcome for Outcome Of Board Meeting

    31 Jul 2026, 5:20PM Outcome of Board Meeting

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Jul 2026, 2:34PM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    22 Jul 2026, 2:31PM Intimation for Schedule of Analysts / Investor Conference

  • Corona Remedies - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Co

    17 Jul 2026, 5:36PM Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and

  • Corona Remedies has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    13 Jul 2026, 1:00PM As of June 2026, 69.00% is owned by Indian Promoters and 31.00% by Public. <p align=justify> Institutional holds 16.53% (Insurance Companies 0.29%) an

  • Corona Remedies - Shareholders meeting

    10 Jul 2026, 4:52PM CORONA Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 09, 2026. Further, the company ha

  • Corona Remedies - Shareholders Meeting / Postal Ballot- Scrutinizer's Report

    10 Jul 2026, 4:49PM Declaration of Voting Results and Scrutinizer's Report for 22nd Annual General Meeting

  • Corona Remedies - Shareholders meeting

    9 Jul 2026, 2:52PM CORONA Remedies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 09, 2026

  • Corona Remedies - Shareholders Meeting / Postal Ballot- Scrutinizer's Report

    10 Jul 2026, 4:49PM Declaration of Voting Results and Scrutinizer's Report for 22nd Annual General Meeting

  • Corona Remedies - Shareholder Meeting / Postal Ballot-Outcome of AGM

    9 Jul 2026, 2:46PM Outcome of 22nd Annual General Meeting

  • Corona Remedies - Shareholders Meeting / Postal Ballot- Scrutinizer's Report

    10 Jul 2026, 4:49PM Declaration of Voting Results and Scrutinizer's Report for 22nd Annual General Meeting

  • Corona Remedies - Shareholders Meeting / Postal Ballot- Scrutinizer's Report

    10 Jul 2026, 4:49PM Declaration of Voting Results and Scrutinizer's Report for 22nd Annual General Meeting

  • Corona Remedies - Shareholders Meeting / Postal Ballot- Scrutinizer's Report

    10 Jul 2026, 4:49PM Declaration of Voting Results and Scrutinizer's Report for 22nd Annual General Meeting

  • Corona Remedies - Shareholders Meeting / Postal Ballot- Scrutinizer's Report

    10 Jul 2026, 4:49PM Declaration of Voting Results and Scrutinizer's Report for 22nd Annual General Meeting

  • Corona Remedies - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Jul 2026, 3:01PM CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Corona Remedies - Compliances-Certificate Under Reg. 74(5) Of SEBI (DP) Regulations, 2018

    6 Jul 2026, 2:56PM Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the first quarter ended June 30, 2026

  • Corona Remedies - Press Release

    30 Jun 2026, 4:50PM CORONA Remedies Limited has informed the Exchange regarding a press release dated Jun 30, 2026, titled ""Press Release for Commencement of Commercial

  • Corona Remedies - Commencement of commercial production/operations

    30 Jun 2026, 4:47PM CORONA Remedies Limited has informed the Exchange about Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Jun 2026, 4:36PM Press Release for Commencement of Commercial Production

  • Corona Remedies - Commencement Of Commercial Production

    30 Jun 2026, 4:34PM Intimation under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015-Commencement

  • Corona Remedies - Trading Window

    29 Jun 2026, 11:41AM CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,

  • Corona Remedies - Copy of Newspaper Publication

    16 Jun 2026, 12:56PM CORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication - Notice of 22nd Annual General Meeting, Intimation of Record da

  • Corona Remedies - Copy of Newspaper Publication

    10 Jun 2026, 5:18PM CORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication - Intimation of 22nd Annual General Meeting of the Company throu

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Jun 2026, 9:11AM CORONA Remedies Limited has informed the Exchange about Schedule of Analysts / Investor Conference

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Jun 2026, 9:15AM Intimation for Schedule of Analysts / Investor Conference

  • Corona Remedies - Disclosure under SEBI Takeover Regulations

    3 Jun 2026, 1:06PM Dr. Kirtikumar L. Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Subst

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Jun 2026, 9:17AM CORONA Remedies Limited has informed the Exchange about Intimation of Non-Deal Roadshow

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Jun 2026, 9:16AM Intimation for Non-Deal Roadshow

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Jun 2026, 11:57AM CORONA Remedies Limited has informed the Exchange about Intimation for Non-Deal Roadshow

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Jun 2026, 11:55AM Intimation for Non-Deal Roadshow

  • Corona Remedies - Press Release

    28 May 2026, 3:38PM CORONA Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled ""Press Release - Receipt of EU-GMP Certificate

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    28 May 2026, 3:35PM Press Release - Receipt of EU-GMP Certification

  • Corona Remedies - Disclosure under SEBI Takeover Regulations

    26 May 2026, 12:44PM CORONA Remedies Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Subst

  • Corona Remedies - Disclosure under SEBI Takeover Regulations

    25 May 2026, 3:55PM Ankur K. Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac

  • Corona Remedies - Disclosure under SEBI Takeover Regulations

    22 May 2026, 10:37AM CORONA Remedies Limitedÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Subst

  • Corona Remedies - Updates

    21 May 2026, 2:45PM CORONA Remedies Limited has informed the Exchange regarding 'Communication to Shareholders - Intimation on Tax Deduction on Dividend'.

  • Corona Remedies - General-Updates

    21 May 2026, 2:42PM Communication to Shareholders - Intimation on Tax Deduction on Dividend

  • Corona Remedies Q4 net profit jumps 43.75% at Rs 45.05 cr

    20 May 2026, 1:30PM The company reported standalone net profit of Rs 45.05 crore for the quarter ended March 31, 2026 as compared to Rs 31.34 crore in the same period las

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    19 May 2026, 11:23AM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    19 May 2026, 11:20AM Intimation of participation in Analyst / Investor Conference

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    18 May 2026, 7:18PM CORONA Remedies Limited has informed the Exchange about Transcript

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    18 May 2026, 7:16PM Transcript of Earnings call with Analyst/Investor on Financial Results for the fourth quarter and year ended March 31, 2026
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Corona Remedies Ltd stock 

Name March-26 March-25
Assets 888.83 668.4207
Liabilities 888.83 668.4207
Equity 61.16 61.1601
Gross Profit 293.44 239.9751
Net Profit 184.85 149.0473
Cash From Operating Activities 229.48 190.4942
NPM(%) 13.17 12.45
Revenue 1403.18 1196.4152
Expenses 1109.74 956.4401
ROE(%) 24.75 19.95

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
19 Jun 2026 10 100 0.47 1755.8

Peers

Other companies within the same industry or sector that are comparable to Corona Remedies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 812.50 1.30 20.55 1223.65 -26.19 0.62
Lotus Eye Hospital and Institute Ltd 115.22 -1.19 1646.00 4458.83 0.39 0.00
Vaishali Pharma Ltd 8.51 0.47 26.59 27971.73 15.42 0.00
Astec Lifesciences Ltd 593.95 -1.35 0.00 4777.39 -363.14 0.00

Company Info

Our Company was originally incorporated as `CORONA Remedies Private Limited', a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to `CORONA Remedies Limited'. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.Major events and milestones:2004- Launch of first division, later named as `Pioneer' division in 20102005- Launch of division (multispeciality): Xemx2007- Commencement of production at the first manufacturing plant at Solan, Himachal Pradesh2008- Launch of division (gynaecology): Aarush2013- Launch of division (cardioloy): Wellness2016- Purchased the trademarks "Stelbid" and "Vitneurin" from Glaxo Group Limited- Purchased the trademarks "Dilo DX" and "Dilo-BM" from GlaxoSmithKline Pharmaceuticals Limited2018- Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis- Acquired the trademarks "Obimet", "Obimet-GX", "Obimet SR", "Obimet-V" "Triobimet" and "Thyrocab" (within India) from Abbott India Limited2020- Entered into a strategic alliance with La Chandra Pharmalab Private Limited2021- Commencement of production at the manufacturing plant at Ahmedabad, Gujarat2022- Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris2023- Launch of division (urology): Blaze- Purchased the trademark "Myoril" (in India) from Sanofi Healthcare India Private Limited- Received EU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat 2025 -Acquisition of 7 trademarks from Bayer Zydus Pharma Ltd.

Our Company was originally incorporated as `CORONA Remedies Private Limited', a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to `CORONA Remedies Limited'. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.Major events and milestones:2004- Launch of first division, later named as `Pioneer' division in 20102005- Launch of division (multispeciality): Xemx2007- Commencement of production at the first manufacturing plant at Solan, Himachal Pradesh2008- Launch of division (gynaecology): Aarush2013- Launch of division (cardioloy): Wellness2016- Purchased the trademarks "Stelbid" and "Vitneurin" from Glaxo Group Limited- Purchased the trademarks "Dilo DX" and "Dilo-BM" from GlaxoSmithKline Pharmaceuticals Limited2018- Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis- Acquired the trademarks "Obimet", "Obimet-GX", "Obimet SR", "Obimet-V" "Triobimet" and "Thyrocab" (within India) from Abbott India Limited2020- Entered into a strategic alliance with La Chandra Pharmalab Private Limited2021- Commencement of production at the manufacturing plant at Ahmedabad, Gujarat2022- Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris2023- Launch of division (urology): Blaze- Purchased the trademark "Myoril" (in India) from Sanofi Healthcare India Private Limited- Received EU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat 2025 -Acquisition of 7 trademarks from Bayer Zydus Pharma Ltd.

Parent Organisation

Corona Remedies Ltd.

Founded

27/08/2004

Managing Director

Mr.Nirav Mehta

NSE Symbol

CORONAEQ

FAQ